Ian Clark

Ian Clark

Net worth: 2 M $ as of 31/08/2026

65 year
Health Technology
Commercial Services
Consumer Non-Durables

Profile

Mr. Ian T.
Clark
is a Chairman at BioMarin Pharmaceutical, Inc., an Independent Director at Kyverna Therapeutics, Inc., a Chairman at Olema Pharmaceuticals, Inc., a Lead Independent Director at Guardant Health, Inc., a Chairman at X-Vax Technology, Inc. and a Member at TechNet.
He is on the Board of Directors at Asher Biotherapeutics, Inc., Kyverna Therapeutics, Inc. and Guardant Health, Inc. Mr. Clark was previously employed as an Independent Director by GoodRx Holdings, Inc., a Non-Executive Director by Gyroscope Therapeutics Holdings Plc, an Independent Director by Takeda Pharmaceutical Co., Ltd., an Independent Director by Forty Seven LLC, an Independent Director by Tectonic Therapeutic, Inc., an Independent Director by Kite Pharma, Inc., an Independent Director by Corvus Pharmaceuticals, Inc., an Independent Non-Executive Director by Shire Plc, an Independent Director by Agios Pharmaceuticals, Inc., an Independent Director by TerraVia Holdings, Inc., a Chief Executive Officer & Director by Genentech, Inc., a Chief Marketing Officer & Executive Vice President by Roche Group, a General Manager by Novartis Pharmaceuticals Canada, Inc., a Chief Operating Officer by Novartis Pharmaceuticals UK Ltd., a Vice President-Sales by Aventis SA, a Member by Economic Advisory Council, a Vice President-Sales & Marketing by IVAX LLC, a Vice President-Sales by IVAX Pharmaceuticals, Inc., a Vice President-Sales & Marketing by Sanofi, and a Member-BioFulcrum Board by The J.
David Gladstone Institutes.
He also served on the board at Shire Pharmaceuticals, Inc., Dendreon Corp., Dendreon Pharmaceuticals LLC, Biotechnology Innovation Organization, Gladstone Foundation (CA), Ligand UK Ltd., Solazyme, Inc., The Bioindustry Association, Vernalis (R&D) Ltd. and Vernalis Therapeutics, Inc. He received his undergraduate degree from The University of Southampton.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
02/06/2026 14,490 ( 0.01% ) 945 183 $ 31/08/2026
18/03/2026 19,396 ( 0% ) 700 197 $ 31/08/2026
04/08/2026 2,975 ( 0% ) 473 085 $ 31/08/2026
27/05/2026 21,727 ( 0.04% ) 184 136 $ 31/08/2026
20/04/2026 43,100 ( 0.04% ) 150 419 $ 31/08/2026
18/06/2026 0 ( -.--% ) - $ 31/08/2026
11/06/2026 0 ( -.--% ) - $ 31/08/2026

Ian Clark active positions

CompaniesPositionStart
GUARDANT HEALTH, INC. Director/Board Member 01/12/2016
OLEMA PHARMACEUTICALS, INC. Chairman 01/08/2020
KYVERNA THERAPEUTICS, INC. Director/Board Member 12/01/2026
BIOMARIN PHARMACEUTICAL INC. Chairman 02/06/2026
Chairman -
Director/Board Member 14/02/2022
Corporate Officer/Principal -

Former positions of Ian Clark

CompaniesPositionEnd
CORVUS PHARMACEUTICALS, INC. Director/Board Member 22/07/2026
TAKEDA PHARMACEUTICAL COMPANY LIMITED Director/Board Member 24/06/2026
░░░░░░ ░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░░░░░ ░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
See the detail of Ian Clark's experience

Training of Ian Clark

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

81

1st degree connections

38

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies38

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Consumer Non-Durables

Commercial Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Finance

Consumer Services

Health Technology

Commercial Services

Health Technology

Commercial Services

Health Technology

Commercial Services

Health Technology

Health Technology

Health Technology

Commercial Services

Health Technology

Health Technology

Distribution Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Services

Health Technology

Solazyme, Inc.

Economic Advisory Council